What factors drove IBRX's record-breaking Q3 2024 EPS?

ImmunityBio Inc. (IBRX) reported a quarterly loss of $0.20 per share in Q2 2024, which included several significant factors driving the company's financial performance:

1. **Increased Research and Development Expenses**: The company's R&D expenses rose to $50.4 million, up from $48.4 million in the same period last year. This increase was primarily due to personnel-related costs, indicating a focus on talent and expertise in the biotech sector.
2. **Higher Selling, General, and Administrative Expenses**: ImmunityBio's SG&A expenses climbed to $35.9 million, up from $31.8 million in the previous year. This rise suggests a strengthening of the company's operational infrastructure and market positioning.
3. **Strategic Investments and Market Positioning**: The company's strategic moves, such as purchasing shares by ProShare Advisors LLC and Bank of New York Mellon Corp buying 170,742 shares, reflect confidence from key investors. These actions can stabilize the stock and signal long-term growth potential, which might influence financial outcomes through improved investor sentiment and potential synergies from collaborative activities.

In conclusion, IBRX's Q3 2024 EPS was driven by significant investments in research and development, increased operational costs, and strategic investments that bolster the company's market position and investor confidence.